JSPR insider transaction filings
Jasper Therapeutics, Inc. — 30 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-04. Screen JSPR transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Shizuru Judith Anne — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | EMSTER KURT VON — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Crutcher Patrick J — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | Lucas Svetlana — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-08-04 | 4 | WIGGANS THOMAS G — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2026-07-22 | 4 | Ros Matthew E — Chief Operating Officer | Purchase (P): 881 (derivative) | EDGAR |
| 2026-07-20 | 4 | Crutcher Patrick J — Director | Grant/award (A): 15,000 (derivative) @ $0 · Purchase (P): 888 (derivative) | EDGAR |
| 2026-02-10 | 4 | Mahal Jeetinder Singh — CEO and President, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | MARTELL RON — President, CEO and Director, Director | Grant/award (A): 234,000 (derivative) @ $0 | EDGAR |
| 2025-09-24 | 4 | Shizuru Judith Anne — Director | Purchase (P): 41,000 @ $2.43 · Purchase (P): 41,000 (derivative) | EDGAR |
| 2025-09-24 | 4 | Lucas Svetlana — Director | Purchase (P): 20,000 @ $2.43 · Purchase (P): 20,000 (derivative) | EDGAR |
| 2025-09-24 | 4 | WIGGANS THOMAS G — Director | Purchase (P): 41,000 @ $2.43 · Purchase (P): 41,000 (derivative) | EDGAR |
| 2025-09-24 | 4 | MARTELL RON — President and CEO, Director | Purchase (P): 41,000 @ $2.43 · Purchase (P): 41,000 (derivative) | EDGAR |
| 2025-07-03 | 4 | Brun Scott C. — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Shizuru Judith Anne — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Kapoor Vishal — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Nolet Chris — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Lucas Svetlana — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | EMSTER KURT VON — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | WIGGANS THOMAS G — Director | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Tucker Edwin Jonathan — Chief Medical Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | MARTELL RON — President and CEO, Director | Grant/award (A): 234,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Mahal Jeetinder Singh — Chief Operating Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | Tucker Edwin Jonathan — Chief Medical Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | CROSS HERB — Chief Financial Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | MARTELL RON — President, CEO and Director, Director | Grant/award (A): 130,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Jasper Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-07-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-07-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-09 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=JSPR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →